NCT01649271 2025-02-11
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
Phase 1 Completed
Clinical Trials
7 trialsNCT04839471 2024-07-08
BEAR
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT01522768 2023-11-01
Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02501603 2023-01-27
Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
Yonsei University
Phase 2 Completed
NCT02451553 2022-06-07
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
University of Washington
Phase 1 Completed
NCT01919879 2018-05-08
Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer
UNICANCER
Phase 2 Completed
NCT00801294 2017-12-29
A Phase II Trial of Weekly Alternating Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Advanced Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed